Advertisement

Pathological Staging of Melanoma

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1102)

Abstract

Staging of cancer is a shorthand system of describing the extent of disease. Pathological staging, often called microstaging, uses the methods of histopathology to achieve this goal. Microstaging for melanoma utilizes attributes that are associated with outcome, generally in association with prognostic models that allow for estimation of survival rates, based on large groups of patients with similar tumors. Microstaging can be performed on primary tumors and to a lesser extent on metastases. Attributes that are important in microstaging in primary tumors include, in particular, those that are utilized in the AJCC/UICC staging system. These are, more or less in order of importance, Breslow's thickness, ulceration, and mitogenicity (the presence or absence of mitoses). Other attributes that have relevance to prognosis at least in some well-conducted studies include tumor-infiltrating lymphocytes, lymphovascular invasion, perineural invasion, Clark's level of invasion, the presence or absence of vertical growth phase and of regression, and other attributes. The pathologic interpretation and significance of these “prognostic variables” are discussed in this chapter. In addition, prognostic models including the AJCC staging system are presented in some detail.

Key words

Melanoma Staging Microstaging AJCC Prognosis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Edge SB, Byrd DR, Compton C, Fritz AG (2009) AJCC cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  2. 2.
    Elder DE, Murphy GF (2011) American registry of pathology, in collaboration with the Armed Forces Institute of Pathology. Melanocytic tumors of the skin, vol 12, Washington, DCGoogle Scholar
  3. 3.
    Karakousis GC, Gimotty PA, Botbyl JD et al (2006) Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 13:1–9CrossRefGoogle Scholar
  4. 4.
    Kesmodel SB, Karakousis GC, Botbyl JD et al (2005) Mitotic rate as a predictor of sentinel lymph nodepositivity in patients with thin melanomas. Ann Surg Oncol 12:449–458PubMedCrossRefGoogle Scholar
  5. 5.
    Clark WH Jr, Elder DE, Guerry DIV et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893–1904PubMedCrossRefGoogle Scholar
  6. 6.
    Lew RA, Day CL Jr, Harrist TJ, Wood WC, Mihm MC Jr (1983) Multivariate analysis. Some guidelines for physicians. JAMA 249:641–643PubMedCrossRefGoogle Scholar
  7. 7.
    Gershenwald JE, Buzaid AC, Ross MI (2000) Classification and staging of melanoma. Clin Lab Med 20:785–815PubMedGoogle Scholar
  8. 8.
    Frishberg DP, Balch C, Balzer BL et al (2009) Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med 133:1560–1567PubMedGoogle Scholar
  9. 9.
    Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206PubMedCrossRefGoogle Scholar
  10. 10.
    Guerry DIV, Synnestvedt M, Elder DE, Schultz D (1993) Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 100:342S–345SPubMedCrossRefGoogle Scholar
  11. 11.
    Elder DE, Guerry DIV, Epstein MN et al (1984) Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 6:55–62PubMedGoogle Scholar
  12. 12.
    Barnhill RL, Fine JA, Roush GC, Berwick M (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78:427–432PubMedCrossRefGoogle Scholar
  13. 13.
    Clark WH Jr (1967) A classification of malignant melanoma in man correlated with histogenesis and biologic behavior. In: Montagna W, Hu F (eds) Advances in the biology of the skin, vol VIII. Pergamon, New York, pp 621–647Google Scholar
  14. 14.
    Gimotty PA, Elder DE, Fraker DL et al (2007) Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 25:1129–1134PubMedCrossRefGoogle Scholar
  15. 15.
    Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902–908PubMedCrossRefGoogle Scholar
  16. 16.
    Schuchter L, Schultz DJ, Synnestvedt M et al (1996) A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med 125:369–375PubMedCrossRefGoogle Scholar
  17. 17.
    Breslow A (1975) Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 182:572–575PubMedCrossRefGoogle Scholar
  18. 18.
    Balch CM, Buzaid AC, Atkins MB et al (2000) A new American Joint Committee on cancer staging system for cutaneous melanoma. Cancer 88:1484–1491PubMedCrossRefGoogle Scholar
  19. 19.
    Day CL Jr, Lew RA, Mihm MC Jr et al (1981) The natural break points for primary-tumor thickness in clinical stage I melanoma. N Engl J Med 305:1155 [letter]PubMedGoogle Scholar
  20. 20.
    Balch CM, Soong S-J, Shaw HM, Milton GW (1985) An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Balch CM, Milton GW, Shaw HM, Soong S-J (eds) Cutaneous melanoma. Clinical management and treatment results worldwide, 1st edn. Lippincott, Philadelphia, pp 321–352Google Scholar
  21. 21.
    Vollmer RT, Seigler HF (2001) Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. Am J Clin Pathol 115:205–212PubMedCrossRefGoogle Scholar
  22. 22.
    Cochran AJ, Bailly C, Cook M et al (1997) Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Hum Pathol 28:1123–1125PubMedCrossRefGoogle Scholar
  23. 23.
    Smolle J (1995) Biological significance of tumor thickness. Theoretical considerations based on computer simulation. Am J Dermatopathol 17:281–286PubMedCrossRefGoogle Scholar
  24. 24.
    Cochran AJ (1968) Method of assessing prognosis in patients with malignant melanoma. Lancet 2:1062–1064PubMedCrossRefGoogle Scholar
  25. 25.
    Schmoeckel C, Braun-Falco O (1978) Prognostic index in maligant melanoma. Arch Dermatol 114:871–873PubMedCrossRefGoogle Scholar
  26. 26.
    Attis MG, Vollmer RT (2007) Mitotic rate in melanoma: a reexamination. Am J Clin Pathol 127:380–384PubMedCrossRefGoogle Scholar
  27. 27.
    Cochran AJ, Elashoff D, Morton DL, Elashoff R (2000) Individualized prognosis for melanoma patients. Hum Pathol 31:327–331PubMedCrossRefGoogle Scholar
  28. 28.
    Gershenwald JE, Soong SJ, Balch CM (2010) 2010 TNM staging system for cutaneous melanoma…and beyond. Ann Surg Oncol 17:1475–1477PubMedCrossRefGoogle Scholar
  29. 29.
    Thompson JF, Soong SJ, Balch CM et al (2011) Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on cancer melanoma staging database. J Clin Oncol 29:2199–2205PubMedCrossRefGoogle Scholar
  30. 30.
    Kruper LL, Spitz FR, Czerniecki BJ et al (2006) Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 107:2436–2445PubMedCrossRefGoogle Scholar
  31. 31.
    Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS (2007) Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25:869–875PubMedCrossRefGoogle Scholar
  32. 32.
    Mandala M, Imberti GL, Piazzalunga D et al (2009) Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer 45:2537–2545PubMedCrossRefGoogle Scholar
  33. 33.
    van Houdt IS, Sluijter BJ, van Leeuwen PA et al (2009) Absence of Granzyme B positive tumour-infiltrating lymphocytes in primary melanoma excisional biopsies is strongly associated with the presence of sentinel lymph node metastasis. Cell Oncol 31:407–413PubMedGoogle Scholar
  34. 34.
    Burton AL, Roach BA, Mays MP et al (2011) Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg 77:188–192PubMedGoogle Scholar
  35. 35.
    Azimi F, Scolyer RA, Rumcheva P et al (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30:2678–2683PubMedCrossRefGoogle Scholar
  36. 36.
    Busam KJ, Antonescu CR, Marghoob AA et al (2001) Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. Am J Clin Pathol 115:856–860PubMedCrossRefGoogle Scholar
  37. 37.
    Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA (2000) Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 13:459–465PubMedCrossRefGoogle Scholar
  38. 38.
    Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M (1999) Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression. Cancer 85:1067–1076PubMedCrossRefGoogle Scholar
  39. 39.
    Taran JM, Heenan PJ (2001) Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. Cancer 91:1822–1825PubMedCrossRefGoogle Scholar
  40. 40.
    Gromet MA, Epstein WL, Blois MS (1978) The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 42:2282–2292PubMedCrossRefGoogle Scholar
  41. 41.
    Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK (1987) Thin malignant melanomas with regression and metastases. Arch Dermatol 123:1326–1330PubMedCrossRefGoogle Scholar
  42. 42.
    Kang S, Barnhill RL, Mihm MC Jr, Sober AJ (1993) Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol 20:126–129PubMedCrossRefGoogle Scholar
  43. 43.
    Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA (1980) The prognostic significance of ulceration of cutaneous melanoma. Cancer 45:3012–3017PubMedCrossRefGoogle Scholar
  44. 44.
    Spatz A, Cook MG, Elder DE, Piepkorn M, Ruiter DJ, Barnhill RL (2003) Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer 39:1861–1865PubMedCrossRefGoogle Scholar
  45. 45.
    Day CL Jr, Harrist TJ, Gorstein F et al (1981) Malignant melanoma. Prognostic significance of “microscopic satellites” in the reticular dermis and subcutaneous fat. Ann Surg 194:108–112PubMedCrossRefGoogle Scholar
  46. 46.
    Harrist TJ, Rigel DS, Day CL Jr et al (1984) “Microscopic satellites” are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 53:2183–2187PubMedCrossRefGoogle Scholar
  47. 47.
    León P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH Jr (1991) The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 126:1461–1468PubMedCrossRefGoogle Scholar
  48. 48.
    Barnhill RL, Lugassy C (2004) Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology 36:485–490PubMedCrossRefGoogle Scholar
  49. 49.
    Xu X, Chen L, Guerry D et al (2011) Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 18:229–237PubMedCrossRefGoogle Scholar
  50. 50.
    Mauri MF, Boi S, Micciolo R, Cristofolini M, Dalla Palma P (1997) Morphometric analysis in prognostic evaluation of stage I thick cutaneous melanomas. Anal Quant Cytol Histol 19:311–315PubMedGoogle Scholar
  51. 51.
    Bjornhagen V, Mansson-Brahme E, Lindholm J, Mattsson A, Auer G (1993) Morphometric, DNA and PCNA in thin malignant melanomas. Med Oncol Tumor Pharmacother 10:87–94PubMedGoogle Scholar
  52. 52.
    Chagpar RB, Ross MI, Reintgen DS et al (2007) Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis. J Surg Res 143:164–168PubMedCrossRefGoogle Scholar
  53. 53.
    Clemente CG, Mihm MG, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310PubMedCrossRefGoogle Scholar
  54. 54.
    Aitchison TC, Sirel JM, Watt DC, MacKie RM (1995) Prognostic trees to aid prognosis in patients with cutaneous malignant melanoma. Scottish Melanoma Group. BMJ 311:1536–1539PubMedCrossRefGoogle Scholar
  55. 55.
    Reintgen DS, Albertini J, Miliotes G (2001) The accurate staging and modern day treatment of malignant melanoma. Cancer Res Ther Control 4:183Google Scholar
  56. 56.
    Stadelmann WK, Rapaport DP, Soong S-J, Reintgen DS, Buzaid AC, Balch CM (1998) Prognostic clinical and pathologic features. In: Balch CM, Houghton AN, Sober AJ, Soong S-J (eds) Cutaneous melanoma, 3rd edn. Quality Medical Publishing, Inc., St Louis, MO, pp 11–36Google Scholar
  57. 57.
    Balch CM, Gershenwald JE, Soong SJ et al (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459PubMedCrossRefGoogle Scholar
  58. 58.
    van der Ploeg AP, van Akkooi AC, Rutkowski P et al (2011) Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and dewar topography criteria. J Clin Oncol 29:2206–2214PubMedCrossRefGoogle Scholar
  59. 59.
    Clark WH Jr, From L, Bernardino EA, Mihm MC Jr (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705–727PubMedGoogle Scholar
  60. 60.
    Breslow A (1980) Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu 15:1–22PubMedGoogle Scholar
  61. 61.
    Soong S-J (1985) A computerized mathematical model and scoring system for predicting outcome in melanoma patients. In: Balch CM, Milton GW, Shaw HM, Soong S-J (eds) Cutaneous melanoma. Clinical management and treatment results worldwide, 1st edn. J.B.Lippincott Company, Philadelphia, pp 353–370Google Scholar
  62. 62.
    Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK (2002) Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118:504–511PubMedCrossRefGoogle Scholar
  63. 63.
    Gimotty PA, Guerry D, Elder DE (2002) Validation of prognostic models for melanoma. Am J Clin Pathol 118:489–491PubMedCrossRefGoogle Scholar
  64. 64.
    Beahrs OH, Myers MH (1983) Manual for staging of cancer. Lippincott, PhiladelphiaGoogle Scholar
  65. 65.
    Buzaid AC, Ross MI, Balch CM et al (1997) Critical analysis of the current American Joint Committee on cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15:1039–1051PubMedGoogle Scholar
  66. 66.
    Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the american joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648PubMedGoogle Scholar
  67. 67.
    Soong SJ, Ding S, Coit D et al (2010) Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database. Ann Surg Oncol 17:2006–2014PubMedCrossRefGoogle Scholar
  68. 68.
    Callender GG, Gershenwald JE, Egger ME et al (2012) A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on cancer model. J Am Coll Surg 214:608–617PubMedCrossRefGoogle Scholar
  69. 69.
    Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:A193–A201Google Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations

Cite protocol

Buy options